analysis is made in the societal cost perspective, adding direct medical costs charged both on the National Health Service and the patient, since orlistat is not reimbursed. Costs and health benefits are discounted at a 3.5% annual rate. RESULTS: The treatment with orlistat of the Italian obese population (estimated in more than 4 million subjects), produces an estimated average increase in quality-adjusted life expectance of 0.05 (0.035-0.065) QALY/patient, an estimated reduction of cardiovascular events and diabetes onsets at an estimated overall increased cost (based on the current orlistat public price) of about 12 (1.7-13.7) million Euro in 10 years. On the Impaired Glucose Tolerance (IGT) patients subgroup (283,000 people), the benefits are relatively larger, and they come at an increased cost of 608 (-1.6-918) thousands Euro. Estimated average (95% CI) cost-utility incremental ratios are 60.8 (9.2-84.5) and 16.34 (-43.5-27.54) thousand Euro/QALY for the whole cohort and the IGT subpopulation, respectively. CONCLUSION: Orlistat shows a good pharmacoeconomic profile, especially in IGT patients, with a cost-utility of 16.340 Euro/QALY. This value is lower than that of several therapeutic strategies commonly accepted in developed countries. OBJECTIVES: Obesity, hypertension and dyslipidemia (low HDL-cholesterol, high triglycerides) are known risk factors (RF) for the development of cardiovascular diseases and diabetes mellitus type 2 (DM). The aim of the study was to develop a decision analytic model as a tool to assess the cost-effectiveness of treatment options of obesity and associated cardiovascular risk factors. METHODS: As part of the German Metabolic and Cardiovascular Risk Project GEMCAS a decision analytic model from the German payer's perspective was developed. RESULTS: The model has a cycle length of one year and consists of nine health states (HS): (HS1) DM without complications and no further RF; (HS2) DM without complications and one further RF (HS3) DM without complications and 2-4 further RF (HS4) DM with microvascular complications (HS5) DM with macrovascular complications (HS6) healthy (HS7) 1-4 RF (HS8) post myocardial infarction or stroke (HS9) death. Annual costs have been assessed for each health state as well as for transitions due to myocardial infarction or stroke: (HS1) 626 Euro (HS2) 794 Euro (HS3) 962 Euro (HS4) 6.276 Euro (HS5) 3.633 Euro (HS6), 0 Euro (HS7), 336 Euro (HS8) 1.710 Euro, transition costs for myocardial infarction are 4.560 Euro and for stroke 4.780 Euro. Target population has a defined risk profile and transition probabilities are calculated using the Framingham Risk Equation for myocardial infarction and stroke. Additionally an independent effect of obesity according to the INTERHEART study was assumed. The development of DM was calculated based on the risk equation from San Antonio Heart Study. CONCLUSION:
analysis is made in the societal cost perspective, adding direct medical costs charged both on the National Health Service and the patient, since orlistat is not reimbursed. Costs and health benefits are discounted at a 3.5% annual rate. RESULTS: The treatment with orlistat of the Italian obese population (estimated in more than 4 million subjects), produces an estimated average increase in quality-adjusted life expectance of 0.05 (0.035-0.065) QALY/patient, an estimated reduction of cardiovascular events and diabetes onsets at an estimated overall increased cost (based on the current orlistat public price) of about 12 (1.7-13.7) million Euro in 10 years. On the Impaired Glucose Tolerance (IGT) patients subgroup (283,000 people), the benefits are relatively larger, and they come at an increased cost of 608 (-1.6-918) thousands Euro. Estimated average (95% CI) cost-utility incremental ratios are 60.8 (9.2-84.5) and 16.34 (-43.5-27.54) thousand Euro/QALY for the whole cohort and the IGT subpopulation, respectively. CONCLUSION: Orlistat shows a good pharmacoeconomic profile, especially in IGT patients, with a cost-utility of 16.340 Euro/QALY. This value is lower than that of several therapeutic strategies commonly accepted in developed countries.
POB4 GEMCAS MODEL-A DECISION ANALYTIC MODEL ASSESSING THE COST-EFFECTIVENESS OF TREATMENTS FOR OBESITY AND ASSOCIATED CARDIOVASCULAR RISK FACTORS
Aidelsburger P 1 , Fuchs SM 1 , Hessel F 2 , Ulle T 1 , Wasem J 3 1 CAREM GmbH, Sauerlach, Germany, 2 Sanofi-Aventis, Berlin, Germany, 3 University of Duisburg-Essen, Essen, Germany OBJECTIVES: Obesity, hypertension and dyslipidemia (low HDL-cholesterol, high triglycerides) are known risk factors (RF) for the development of cardiovascular diseases and diabetes mellitus type 2 (DM). The aim of the study was to develop a decision analytic model as a tool to assess the cost-effectiveness of treatment options of obesity and associated cardiovascular risk factors. METHODS: As part of the German Metabolic and Cardiovascular Risk Project GEMCAS a decision analytic model from the German payer's perspective was developed. RESULTS: The model has a cycle length of one year and consists of nine health states (HS): (HS1) DM without complications and no further RF; (HS2) DM without complications and one further RF (HS3) DM without complications and 2-4 further RF (HS4) DM with microvascular complications (HS5) DM with macrovascular complications (HS6) healthy (HS7) 1-4 RF (HS8) post myocardial infarction or stroke (HS9) death. Annual costs have been assessed for each health state as well as for transitions due to myocardial infarction or stroke: (HS1) 626 Euro (HS2) 794 Euro (HS3) 962 Euro (HS4) 6.276 Euro (HS5) 3.633 Euro (HS6), 0 Euro (HS7), 336 Euro (HS8) 1.710 Euro, transition costs for myocardial infarction are 4.560 Euro and for stroke 4.780 Euro. Target population has a defined risk profile and transition probabilities are calculated using the Framingham Risk Equation for myocardial infarction and stroke. Additionally an independent effect of obesity according to the INTERHEART study was assumed. The development of DM was calculated based on the risk equation from San Antonio Heart Study. CONCLUSION: The presented model is a valuable tool to assess the costeffectiveness of different treatments options and can be adopted for new interventions easily.
POB5 QUANTIFYING THE QUALITY OF ECONOMIC EVALUATIONS OF OBESITY INTERVENTIONS: A CRITICAL APPRAISAL OF THE LITERATURE
Redekop WK 1 , Kortram Z 2 1 Erasmus Medical Center, Rotterdam, The Netherlands, 2 Erasmus University, Rotterdam, The Netherlands OBJECTIVES: Given the increasing frequency of obesity and the costs associated with it, it is vital to determine which interventions are effective and cost-effective versus the alternatives. A crucial step in both cases is a critical appraisal of the literature. This study examined the quality of economic evaluations (EE) of obesity interventions using a quantitative approach. METHODS: Economic evaluations were selected using the NHS Economic Evaluations Database (NHS EED, York UK) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) . Quality was based on the method by Chiou (2003) because its development involved many health economists and it provides an overall quality score (range: -1100) using 16 criteria. Associations between study characteristics and quality were examined using regression analysis. Characteristics included publication year, type of intervention (including diet, behaviour, medicine, surgery, combined intervention), source of effectiveness data (single study, literature review), country of evaluation, and source of funding. RESULTS: Thirty-four EEs were identified and all of them fulfilled only some criteria. The most common weaknesses were no discussion of potential biases and inappropriate time horizon or discounting method. Mean overall score was 52 (range: 24-76, SD: 13). Recent EEs were better than older ones (+1.5 points/year) and European EEs were better (15 points) than non-European ones. Source of effectiveness data and source of funding were not associated with quality after adjustment for year and country. Type of intervention was never associated with quality. CONCLUSION: The average quality of EEs seems moderate given a score of 52/100. There is much room for improvement and examination of individual criteria is indispensable in achieving this. Determination of overall quality scores is not an adequate substitute for a critical appraisal. Sometimes a single weakness in a "very good" EE can be fatal and render cost-effectiveness estimates useless. In contrast, elements of a "poor" EE can be valuable when determining the costeffectiveness of an intervention.
PAIN-Clinical Outcomes Studies

PPN1
INCIDENCE OF ACUTE PAIN IN TURKEY
Tulunay FC 1 , Malhan S 2 1 Ankara University Medical School, Ankara, Turkey, 2 Baskent University, Faculty of Health Sciences, Ankara, Turkey OBJECTIVES: Despite being a common problem, there is no published epidemiological data on pain in Turkey. This large scale survey had the main objective of demonstrating the incidence of acute pain, but also sought to explore how individuals perceive their pain, the impact it had on their lives, their perception of the attitudes of others towards their pain, treatments received and the adequacy of treatment. METHODS: Screening interviews identified respondents aged Ն18 years with acute pain, for in-depth interviews. It addressed the following aims: a) estimating the incidence of acute pain in Turkey; b) quantifying causes of acute pain; c) exploring the demographics of acute pain; d) exploring the impact of acute pain on individual's quality of life and daily activities e) understanding current treatment practices. RESULTS: Six percent of the respondents had acute pain. Sixty-seven percent of the 313 respondents willing to participate, had pain due to another disease, 33% of them did not have any disease related to Abstracts A463 their pain. Their pain intensity during last episode of pain was 5 on a 10-point Numeric Rating Scale (NRS). 39% of the respondents had moderate pain (NRS = 5-7), 43% had severe pain (NRS = 7), 67% had headaches, 22% had back pain. 96% of the acute pain sufferers were using drugs for last three months. 96% of them were taking Aspirin® (acetyl salicilic acid), 91% Vermidon® (paracetamol), 90% Novalgin® (Dipyrone), and 80% Apranax® (naproxen sodium). CONCLUSION: Six percent of Turkish adults had acute pain. Sixty-seven percent of the respondents who had acute pain had accompying disease causing the pain. Pain is a major health care problem in Turkey that needs to be evaluated and researched in depth.
PAIN-Cost Studies PPN2 A COST MINIMIZATION ANALYSIS OF IV BOLUS VERSUS IV INFUSION DICLOFENAC IN POST-OPERATIVE PAIN
Wallerstein KRB Pharma Focus, Belle Mead, NJ, USA OBJECTIVES: There are two forms of injectable IV diclofenac available (Dyloject bolus and Voltarol infusion). We conducted a cost minimization analysis to determine the total cost of each treatment strategy. METHODS: A decision-analytic model was developed to estimate total treatment costs of IV bolus versus IV infusion diclofenac. The modeled population was patients who post-operatively would require injectable NSAIDs to control their pain. The model timeframe was for the duration that a patient required post-operative pain management with injectable medication. The model inputs included the actual/estimated cost of medicines, the cost of the IV administration process (staff time and consumables), and the cost of treating adverse events (staff time, medicines and consumables). The unit costs and resources are based on UK data. The results are expressed as Pounds Sterling and as average cost per patient. One-way sensitivity analyses were also conducted on key parameters. RESULTS: The total cost of treating post-operative pain was less with IV bolus diclofenac (Dyloject) than with IV infusion diclofenac (Voltarol). Diclofenac IV bolus cost a mean Յ27.84 per patient overall versus diclofenac IV infusion mean cost of Յ78.61 per patient. The difference in overall cost is attributable to the cost of NSAIDs (IV bolus Յ12.19 versus Յ1.69 IV Infusion), the cost of administering the NSAID (IV bolus Յ9.72 versus Յ49.73 IV Infusion) and the cost of consumables (IV bolus Յ1.40 versus Յ16.72 IV infusion). The difference in the costs of rescue medication (IV bolus Յ2.48 versus Յ6.14 IV infusion) and of treating adverse events (IV bolus Յ2.061 versus Յ4.33 IV infusion) was less. One-way sensitivity analyses show the results are sensitive to the cost of staff time and consumables. CONCLUSION: Diclofenac IV bolus (Dyloject) is cost saving relative to diclofenac IV infusion (Voltarol) in the treatment of post-operative pain.
PPN3 EXPECTED COST AND COST CONSIDERATIONS ASSOCIATED WITH OPIOID ROTATION FOR CHRONIC NON-CANCER PAIN: A SIMULATION MODEL
Magar RS 1 , Fine PG 2 , White RE 3 1 PPD, Morrisville, NC, USA, 2 University of Utah-Pain Research Center, Salt Lake City, UT, USA, 3 Endo Pharmaceuticals, Chadds Ford, PA, USA OBJECTIVES: To develop an expected-cost model to examine the impact of opioid rotation among patients with chronic noncancer pain from the payor perspective METHODS: A decision tree was developed depicting pathways a patient may follow over the course of 1 year while taking long acting opioids. Up to 2 switches and 5 dose adjustments were possible for each of the three treatment arms: 1) MS Contin ER switch to OPANA ER; 2) MS Contin ER switch to OxyContin ER; and 3) OPANA ER switch to OxyContin ER for patients where morphine is not an appropriate first line treatment option. Cost data included drug acquisition costs for extended release (ER) and immediate release (IR) opioids, physician contact reimbursement for pain specialists and primary care physicians. Estimated rates for side effects were assumed similar for the most frequently reported side effects (constipation, nausea, somnolence and sedation) and were applied to all treatment arms. RESULTS: A total of 149 possible pathways of care were evaluated among the 3 treatment arms. Assuming a BID regimen, expected-cost range for treatments 1, 2, and 3 were: $3426-$4299, $3829-$5073, and $4556-$5098, respectively. IR cost contribution of the total expected-cost for treatment arms 1, 2, and 3 amounted to 17%, 21% and 24%, respectively, and was dependent on the total daily ER dose. CONCLUSION: Opioid rotation is thought to be the result of the need to switch opioids when a therapy is not well tolerated by the patient. Having an effective alternative for rotation/switching if first line treatment fails has the potential to reduce incremental down stream costs by decreasing physician contacts due to dose adjustment or the need for further switching. Furthermore, the lack of effective pain management combined with non-tolerated side effects may also require the need for additional medications for pain (IR) and side effects.
